Our previous studies have demonstrated the involvement of xeroderma pigmentosum group A ( XPA ) codon23 and xeroderma pigmentosum group D ( XPD ) codon751 single-nucleotide polymorphisms ( SNPs ) in clinical response to platinum based chemotherapy in advanced NSCLC patients .